Who Buys Sunitinib from India — 188 Importers Behind a $63.6M Market

The importation of Sunitinib from India involves various buyer segments, each with distinct purchasing behaviors:

• Pharmaceutical Companies: Entities like TARO PHARMACEUTICALS INC. (Canada) and SUN PHARMACEUTICAL INDUSTRIES INC. (United States) are prominent buyers, accounting for significant portions of the total import value. These companies typically procure large quantities to support their manufacturing and distribution operations, ensuring a steady supply chain for their markets.

• Distributors: Organizations such as NORTHSTAR DISTRIBUTION CENTER 8912 (United States) and YUSEN LOGISTICS BENELUX BELGIUM (Belgium) function as intermediaries, purchasing Sunitinib in bulk and supplying it to various healthcare providers. Their buying patterns are influenced by market demand and inventory management strategies.

• Regional Subsidiaries: Entities like SUN PHARMA CANADA INC. (Canada) and SUN PHARMA ANZ PTY LTD (Canada) represent regional arms of larger pharmaceutical companies. They import Sunitinib to cater to specific regional markets, aligning their procurement with local demand and regulatory requirements.

• Contract Manufacturers: Companies such as RANBAXY (MALAYSIA) SDN BHD (Malaysia) may act as contract manufacturers, importing Sunitinib for formulation and packaging before distribution. Their procurement is typically project-based, depending on contractual agreements and production schedules.

Each segment's purchasing behavior reflects its role in the pharmaceutical supply chain, with factors like market demand, regulatory compliance, and strategic partnerships influencing order patterns.

The top five importing countries have distinct regulatory frameworks for importing Sunitinib:

• Canada:
• Regulatory Authority: Health Canada.
• Import Registration Process: Importers must obtain a Drug Establishment License (DEL) and ensure the product complies with the Food and Drugs Act and Regulations. Exceptional importation may be permitted during drug shortages, as indicated in Health Canada's archived lists.
• Estimated Timeline for Registration: The DEL application process can take several months, depending on the completeness of the submission and compliance with regulatory requirements.
• Import Tariff/Duty for HS 30049099: Pharmaceutical products under HS code 30049099 are typically duty-free in Canada, but importers should verify current tariff schedules.

• United States:
• Regulatory Authority: U.S. Food and Drug Administration (FDA).
• Import Registration Process: Importers must ensure Sunitinib is FDA-approved and comply with the Drug Supply Chain Security Act (DSCSA). The FDA's Safe Importation Action Plan outlines pathways for importing certain prescription drugs from Canada.
• Estimated Timeline for Registration: Timelines vary based on the importation pathway; state-sponsored programs may require several months for approval.
• Import Tariff/Duty for HS 30049099: Pharmaceutical products under this HS code are generally duty-free, but importers should confirm with U.S. Customs and Border Protection.

• Peru:
• Regulatory Authority: Dirección General de Medicamentos, Insumos y Drogas (DIGEMID).
• Import Registration Process: Importers must register pharmaceutical products with DIGEMID, providing documentation on product quality, safety, and efficacy.
• Estimated Timeline for Registration: The registration process can take approximately 6 to 12 months, depending on the complexity of the application.
• Import Tariff/Duty for HS 30049099: Pharmaceutical imports may be subject to tariffs; importers should consult the latest tariff schedules from Peruvian customs authorities.

• Belgium:
• Regulatory Authority: Federal Agency for Medicines and Health Products (FAMHP).
• Import Registration Process: Importers must obtain a marketing authorization from FAMHP, ensuring compliance with European Medicines Agency (EMA) standards.
• Estimated Timeline for Registration: The process typically takes 7 to 12 months, depending on the completeness of the dossier and any additional information requests.
• Import Tariff/Duty for HS 30049099: As an EU member, Belgium generally applies a 0% tariff on pharmaceutical products under this HS code, but importers should verify current rates.

• Australia:
• Regulatory Authority: Therapeutic Goods Administration (TGA).
• Import Registration Process: Importers must register Sunitinib in the Australian Register of Therapeutic Goods (ARTG) and comply with TGA regulations.
• Estimated Timeline for Registration: The registration process can take 12 to 18 months, depending on the quality of the submission and any additional data requirements.
• Import Tariff/Duty for HS 30049099: Pharmaceutical products under this HS code are typically duty-free in Australia, but importers should confirm with the Australian Border Force.

The demand for Sunitinib in importing countries is driven by several factors:

• Disease Prevalence: Sunitinib is primarily used to treat certain types of cancer, including renal cell carcinoma and gastrointestinal stromal tumors. The prevalence of these cancers influences demand, with higher incidence rates leading to increased need for effective treatments.

• Government Healthcare Programs: Many countries have national health programs that subsidize or fully cover the cost of essential medicines, including cancer treatments. For instance, China's National Reimbursement Drug List includes targeted therapies, impacting procurement patterns.

• Universal Health Coverage Expansion: Efforts to expand universal health coverage increase access to essential medicines. Countries investing in healthcare infrastructure and coverage are likely to see a rise in demand for drugs like Sunitinib.

• WHO Essential Medicines List Procurement: Inclusion of medicines in the WHO Essential Medicines List encourages countries to procure these drugs to meet public health needs. While Sunitinib's inclusion status should be verified, its recognition can drive procurement.

• Tender-Based Purchasing: Many governments and large healthcare providers use tender systems to procure medicines, aiming for cost-effectiveness and supply security. This approach can lead to bulk purchasing and stable demand for Sunitinib.

With 188 buyers across 76 countries, the global market for Sunitinib reflects a broad and sustained demand, influenced by healthcare policies, disease burden, and procurement strategies.

The importation of Sunitinib from India involves various buyer segments, each with distinct purchasing behaviors:

• Pharmaceutical Companies: Entities like TARO PHARMACEUTICALS INC. (Canada) and SUN PHARMACEUTICAL INDUSTRIES INC. (United States) are prominent buyers, accounting for significant portions of the total import value. These companies typically procure large quantities to support their manufacturing and distribution operations, ensuring a steady supply chain for their markets.

• Distributors: Organizations such as NORTHSTAR DISTRIBUTION CENTER 8912 (United States) and YUSEN LOGISTICS BENELUX BELGIUM (Belgium) function as intermediaries, purchasing Sunitinib in bulk and supplying it to various healthcare providers. Their buying patterns are influenced by market demand and inventory management strategies.

• Regional Subsidiaries: Entities like SUN PHARMA CANADA INC. (Canada) and SUN PHARMA ANZ PTY LTD (Canada) represent regional arms of larger pharmaceutical companies. They import Sunitinib to cater to specific regional markets, aligning their procurement with local demand and regulatory requirements.

• Contract Manufacturers: Companies such as RANBAXY (MALAYSIA) SDN BHD (Malaysia) may act as contract manufacturers, importing Sunitinib for formulation and packaging before distribution. Their procurement is typically project-based, depending on contractual agreements and production schedules.

Each segment's purchasing behavior reflects its role in the pharmaceutical supply chain, with factors like market demand, regulatory compliance, and strategic partnerships influencing order patterns.

The top five importing countries have distinct regulatory frameworks for importing Sunitinib:

• Canada:
• Regulatory Authority: Health Canada.
• Import Registration Process: Importers must obtain a Drug Establishment License (DEL) and ensure the product complies with the Food and Drugs Act and Regulations. Exceptional importation may be permitted during drug shortages, as indicated in Health Canada's archived lists.
• Estimated Timeline for Registration: The DEL application process can take several months, depending on the completeness of the submission and compliance with regulatory requirements.
• Import Tariff/Duty for HS 30049099: Pharmaceutical products under HS code 30049099 are typically duty-free in Canada, but importers should verify current tariff schedules.

• United States:
• Regulatory Authority: U.S. Food and Drug Administration (FDA).
• Import Registration Process: Importers must ensure Sunitinib is FDA-approved and comply with the Drug Supply Chain Security Act (DSCSA). The FDA's Safe Importation Action Plan outlines pathways for importing certain prescription drugs from Canada.
• Estimated Timeline for Registration: Timelines vary based on the importation pathway; state-sponsored programs may require several months for approval.
• Import Tariff/Duty for HS 30049099: Pharmaceutical products under this HS code are generally duty-free, but importers should confirm with U.S. Customs and Border Protection.

• Peru:
• Regulatory Authority: Dirección General de Medicamentos, Insumos y Drogas (DIGEMID).
• Import Registration Process: Importers must register pharmaceutical products with DIGEMID, providing documentation on product quality, safety, and efficacy.
• Estimated Timeline for Registration: The registration process can take approximately 6 to 12 months, depending on the complexity of the application.
• Import Tariff/Duty for HS 30049099: Pharmaceutical imports may be subject to tariffs; importers should consult the latest tariff schedules from Peruvian customs authorities.

• Belgium:
• Regulatory Authority: Federal Agency for Medicines and Health Products (FAMHP).
• Import Registration Process: Importers must obtain a marketing authorization from FAMHP, ensuring compliance with European Medicines Agency (EMA) standards.
• Estimated Timeline for Registration: The process typically takes 7 to 12 months, depending on the completeness of the dossier and any additional information requests.
• Import Tariff/Duty for HS 30049099: As an EU member, Belgium generally applies a 0% tariff on pharmaceutical products under this HS code, but importers should verify current rates.

• Australia:
• Regulatory Authority: Therapeutic Goods Administration (TGA).
• Import Registration Process: Importers must register Sunitinib in the Australian Register of Therapeutic Goods (ARTG) and comply with TGA regulations.
• Estimated Timeline for Registration: The registration process can take 12 to 18 months, depending on the quality of the submission and any additional data requirements.
• Import Tariff/Duty for HS 30049099: Pharmaceutical products under this HS code are typically duty-free in Australia, but importers should confirm with the Australian Border Force.

The demand for Sunitinib in importing countries is driven by several factors:

• Disease Prevalence: Sunitinib is primarily used to treat certain types of cancer, including renal cell carcinoma and gastrointestinal stromal tumors. The prevalence of these cancers influences demand, with higher incidence rates leading to increased need for effective treatments.

• Government Healthcare Programs: Many countries have national health programs that subsidize or fully cover the cost of essential medicines, including cancer treatments. For instance, China's National Reimbursement Drug List includes targeted therapies, impacting procurement patterns.

• Universal Health Coverage Expansion: Efforts to expand universal health coverage increase access to essential medicines. Countries investing in healthcare infrastructure and coverage are likely to see a rise in demand for drugs like Sunitinib.

• WHO Essential Medicines List Procurement: Inclusion of medicines in the WHO Essential Medicines List encourages countries to procure these drugs to meet public health needs. While Sunitinib's inclusion status should be verified, its recognition can drive procurement.

• Tender-Based Purchasing: Many governments and large healthcare providers use tender systems to procure medicines, aiming for cost-effectiveness and supply security. This approach can lead to bulk purchasing and stable demand for Sunitinib.

With 188 buyers across 76 countries, the global market for Sunitinib reflects a broad and sustained demand, influenced by healthcare policies, disease burden, and procurement strategies.